Last reviewed 2026-04-20 · How we verify

Peginterferon

At a glance

Approved indications

• Chronic hepatitis C
• Chronic type B viral hepatitis

Common side effects

• Influenza-like illness
• Headache
• Chills
• Injection site erythema
• Injection site pain
• Pain
• Pyrexia
• Myalgia
• Asthenia
• Injection site pruritus
• Arthralgia

Key clinical trials

• An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
• VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B (PHASE2)
• Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia (PHASE2)
• Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma (PHASE2)
• Safety, Tolerability, and Preliminary Efficacy of Peginterferon α-2b in Combination With an Anti-PD-1 Antibody in Patients With Advanced or Metastatic Malignant Solid Tumors (NA)
• DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma (PHASE1, PHASE2)
• Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma (PHASE1)
• Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Peginterferon CI brief — competitive landscape report
• Peginterferon updates RSS · CI watch RSS
• Ziv Hospital portfolio CI